-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Downgrades Seres Therapeutics to Neutral, Raises Price Target to $6

Benzinga·05/08/2025 11:14:24
Listen to the news
Chardan Capital analyst Keay Nakae downgrades Seres Therapeutics (NASDAQ:MCRB) from Buy to Neutral and raises the price target from $1.25 to $6.